EA202091256A1 - Новые антагонисты рецептора брадикинина - Google Patents

Новые антагонисты рецептора брадикинина

Info

Publication number
EA202091256A1
EA202091256A1 EA202091256A EA202091256A EA202091256A1 EA 202091256 A1 EA202091256 A1 EA 202091256A1 EA 202091256 A EA202091256 A EA 202091256A EA 202091256 A EA202091256 A EA 202091256A EA 202091256 A1 EA202091256 A1 EA 202091256A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compound
receptor
present
new antagonists
bradikinin
Prior art date
Application number
EA202091256A
Other languages
English (en)
Inventor
Кристоф Гибсон
Йорн Заупе
Хорст-Дитер Амбрози
Ларс Оле Хауштедт
Original Assignee
Фарварис Нетерлендс Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фарварис Нетерлендс Б.В. filed Critical Фарварис Нетерлендс Б.В.
Publication of EA202091256A1 publication Critical patent/EA202091256A1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Настоящее изобретение относится к соединению общей формулы (I), которое действует как антагонист рецептора брадикинина (BK) B2; к фармацевтической композиции, содержащей одно или более соединений, предлагаемых в настоящем изобретении; к комбинированному продукту, содержащему по меньшей мере одно соединение, предлагаемое в настоящем изобретении, и по меньшей мере один дополнительный активный фармацевтический ингредиент; и к применению указанного соединения (соединений), включая их применение в качестве лекарственного средства.
EA202091256A 2017-11-24 2018-11-23 Новые антагонисты рецептора брадикинина EA202091256A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17203675 2017-11-24
PCT/EP2018/082338 WO2019101906A1 (en) 2017-11-24 2018-11-23 Novel bradykinin b2 receptor antagonists

Publications (1)

Publication Number Publication Date
EA202091256A1 true EA202091256A1 (ru) 2020-10-05

Family

ID=60473364

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091256A EA202091256A1 (ru) 2017-11-24 2018-11-23 Новые антагонисты рецептора брадикинина

Country Status (28)

Country Link
US (3) US10836748B2 (ru)
EP (2) EP3713928B1 (ru)
JP (2) JP7164619B2 (ru)
KR (1) KR102413321B1 (ru)
CN (1) CN111433196B (ru)
AR (1) AR113839A1 (ru)
AU (1) AU2018371186B2 (ru)
BR (1) BR112020010298A2 (ru)
CA (1) CA3082948A1 (ru)
DK (1) DK3713928T3 (ru)
EA (1) EA202091256A1 (ru)
ES (1) ES2908409T3 (ru)
HR (1) HRP20220429T1 (ru)
HU (1) HUE058217T2 (ru)
IL (1) IL274883B2 (ru)
LT (1) LT3713928T (ru)
MA (1) MA50804B1 (ru)
MX (1) MX2020005287A (ru)
NZ (1) NZ764304A (ru)
PH (1) PH12020550683A1 (ru)
PL (1) PL3713928T3 (ru)
PT (1) PT3713928T (ru)
RS (1) RS63087B1 (ru)
SG (1) SG11202004653TA (ru)
SI (1) SI3713928T1 (ru)
TW (1) TWI768156B (ru)
UY (1) UY37981A (ru)
WO (1) WO2019101906A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7164619B2 (ja) 2017-11-24 2022-11-01 ファルバリス ネザーランズ ベー.ヴェー. 新規ブラジキニンb2受容体アンタゴニスト
UY38706A (es) * 2019-05-23 2020-12-31 Pharvaris Gmbh Antagonistas cíclicos del receptor b2 de bradiquinina
UY38707A (es) 2019-05-23 2020-12-31 Pharvaris Gmbh Nuevos antagonistas cíclicos del receptor b2 de bradiquinina
CN116685353A (zh) 2020-11-12 2023-09-01 法瓦里斯有限责任公司 血管性水肿的预防和治疗
WO2023012322A1 (en) 2021-08-05 2023-02-09 Pharvaris Gmbh Lipid-based composition for oral administration of bradykinin b2-receptor antagonists
WO2023012324A1 (en) 2021-08-05 2023-02-09 Pharvaris Gmbh Solid form of a bradykinin b2-receptor antagonist
TW202345810A (zh) 2022-03-25 2023-12-01 瑞士商帕法瑞斯有限責任公司 包含緩激肽b2受體拮抗劑之固態延長釋放組成物
WO2023180577A1 (en) 2022-03-25 2023-09-28 Pharvaris Gmbh Therapeutic uses of bradykinin b2-receptor antagonists
WO2023180575A1 (en) 2022-03-25 2023-09-28 Pharvaris Gmbh Solid composition comprising solubilised bradykinin b2-receptor antagonists

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU680870B2 (en) 1993-04-28 1997-08-14 Astellas Pharma Inc. New heterocyclic compounds
KR970707098A (ko) 1994-10-27 1997-12-01 후지야마 아키라 브라디키닌 길항제로서 피리도피리미돈, 퀴놀린 및 융합된 N-헤테로사이클(Pyridopyrimidones, quinolines and fused N-heterocycles as bradykinin antagonists)
FR2737892B1 (fr) 1995-08-17 1997-10-24 Fournier Ind & Sante Nouveaux composes de benzenesulfonamide, procede de preparation et utilisation en therapeutique
GB9602029D0 (en) 1996-02-01 1996-04-03 Fujisawa Pharmaceutical Co New heterocyclic compounds
DE19609827A1 (de) 1996-03-13 1997-09-18 Hoechst Ag Aminoalkyl- und Acylaminoalkylether, Verfahren zu deren Herstellung und ihre Verwendung als Bradykinin-Rezeptorantagonisten
DE19610784A1 (de) 1996-03-19 1997-09-25 Hoechst Ag Fluoralkyl- und Fluoralkoxysubstituierte heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung
DE19612067A1 (de) 1996-03-27 1997-10-02 Hoechst Ag Verwendung von Bradykinin-Antagonisten zur Herstellung von Arzneimitteln zur Behandlung von chronisch fibrogenetischen Lebererkrankungen und akuten Lebererkrankungen
AUPN952696A0 (en) * 1996-04-29 1996-05-23 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds
DE19712960A1 (de) 1997-03-27 1998-10-01 Hoechst Ag Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten
CA2319730A1 (en) 1998-06-08 1999-12-16 Advanced Medicine, Inc. Bradykinin antagonists
CA2347001A1 (en) 1998-10-21 2000-04-27 Fujisawa Pharmaceutical Co., Ltd. Vitreous form of known bradykinin antagonist
FR2790260B1 (fr) 1999-02-26 2001-05-04 Fournier Ind & Sante Nouveaux composes de n-(benzenesulfonamide), procede de preparation et utilisation en therapeutique
GB9913079D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
WO2001056995A1 (en) 2000-01-18 2001-08-09 Nuerogen Corporation Substituted imidazoles as selective modulators of bradykinin b2 receptors
CA2364178C (en) 2000-12-05 2006-01-10 Yasuhiro Katsu N-benzenesulfonyl l-proline compounds as bradykinin antagonists
WO2003087090A2 (en) 2002-04-10 2003-10-23 Ortho-Mcneil Pharmaceutical,Inc. Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators
ITMI20021247A1 (it) 2002-06-07 2003-12-09 Menarini Ricerche Spa Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche
ITMI20041963A1 (it) 2004-10-15 2005-01-15 Luso Farmaco Inst "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche"
EP1741444A1 (en) 2005-07-05 2007-01-10 Jerini AG Kinin antagonists for treating bladder dysfunction
TWI407960B (zh) * 2007-03-23 2013-09-11 Jerini Ag 小分子緩激肽b2受體調節劑
AR073304A1 (es) * 2008-09-22 2010-10-28 Jerini Ag Moduladores del receptor de bradiquinina b2 de molecula pequena
RU2015138443A (ru) 2013-03-14 2017-04-20 Шир Хьюман Дженетик Терапис, Инк. Способы лечения ангионевротического отека, опосредованного рецепторами брадикинина в2
JP7164619B2 (ja) 2017-11-24 2022-11-01 ファルバリス ネザーランズ ベー.ヴェー. 新規ブラジキニンb2受容体アンタゴニスト

Also Published As

Publication number Publication date
PH12020550683A1 (en) 2021-03-15
PT3713928T (pt) 2022-03-08
EP3713928B1 (en) 2022-01-12
TWI768156B (zh) 2022-06-21
HUE058217T2 (hu) 2022-07-28
US20210017158A1 (en) 2021-01-21
MX2020005287A (es) 2020-08-13
IL274883A (en) 2020-07-30
RS63087B1 (sr) 2022-04-29
AU2018371186A1 (en) 2020-05-28
MA50804B1 (fr) 2022-05-31
AU2018371186B2 (en) 2022-05-12
LT3713928T (lt) 2022-05-10
AR113839A1 (es) 2020-06-17
NZ764304A (en) 2024-02-23
US11820756B2 (en) 2023-11-21
IL274883B2 (en) 2023-11-01
CN111433196A (zh) 2020-07-17
CA3082948A1 (en) 2019-05-31
US20200255405A1 (en) 2020-08-13
JP2023002701A (ja) 2023-01-10
KR20200094174A (ko) 2020-08-06
UY37981A (es) 2019-06-28
JP7164619B2 (ja) 2022-11-01
MA50804A (fr) 2020-09-30
US10836748B2 (en) 2020-11-17
EP3998259A1 (en) 2022-05-18
US20220135543A1 (en) 2022-05-05
US11261173B2 (en) 2022-03-01
PL3713928T3 (pl) 2022-07-11
SG11202004653TA (en) 2020-06-29
CN111433196B (zh) 2023-06-06
DK3713928T3 (da) 2022-04-04
ES2908409T3 (es) 2022-04-29
HRP20220429T1 (hr) 2022-05-27
TW202017916A (zh) 2020-05-16
SI3713928T1 (sl) 2022-09-30
EP3713928A1 (en) 2020-09-30
WO2019101906A1 (en) 2019-05-31
JP2021504464A (ja) 2021-02-15
KR102413321B1 (ko) 2022-06-24
BR112020010298A2 (pt) 2020-11-17
IL274883B1 (en) 2023-07-01

Similar Documents

Publication Publication Date Title
EA202091256A1 (ru) Новые антагонисты рецептора брадикинина
EA201990851A1 (ru) Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
EA201890573A1 (ru) Новые замещенные 6-6-бициклическим ароматическим кольцом аналоги нуклеозидов для применения в качестве ингибиторов prmt5
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
EA202090486A2 (ru) Соединения для лечения спинальной мышечной атрофии
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
EA201792421A1 (ru) Амидозамещенные производные циклогексана
MX2019002180A (es) Moduladores alostericos positivos del receptor m1 muscarinico.
EA201692542A1 (ru) Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы
EA202190960A1 (ru) Конденсированные пирролины, которые действуют как ингибиторы убиквитин-специфической протеазы 30 (usp30)
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
EA202091262A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
EA201890532A1 (ru) Новые аннелированные бензамиды
PH12019500731A1 (en) Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
CO2018001383A2 (es) Derivados de n-[piridin-4-il]metil]-4-{(1r)-1-[(3s)-3-metil-2,5-dioxopirrolidin-3-il]etil}benzamida como antagonistas del receptor cgrp”
MX2015011536A (es) Nuevos antagonistas de receptores trpa1 de sulfamidas.
UY38707A (es) Nuevos antagonistas cíclicos del receptor b2 de bradiquinina
MX2020005483A (es) Antagonistas de ildr2 y combinaciones de los mismos.
EA201890906A1 (ru) ПРОИЗВОДНЫЕ ХИНОКСАЛИНА И ПИРИДОПИРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
EA201692298A1 (ru) Производные карбоксамидов
EA201691160A1 (ru) Антагонисты s1p3
EA201692300A1 (ru) Производные карбоксамида
PH12020551341A1 (en) 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof
ZA202001780B (en) Bezimidazole derivatives as adenosine receptor antagonists
EA202090995A1 (ru) Полициклические амиды в качестве положительных аллостерических модуляторов мускариновых рецепторов м1